Study shows sildenafil cream 3.6% improves sexual arousal in diverse women with FSAD, offering hope for millions seeking effective treatment.

The USPSTF has issued a draft recommendation on cervical cancer screening, find out what physicians need to know.

A new study underscores the critical need for gynecologists and mental health professionals to collaborate in managing anxiety, depression, and sexual dysfunction in women with endometriosis, driven by chronic pain and related comorbidities.

Advances in reproductive technology are making pregnancies over the age of 50 years possible, but they come with unique challenges, requiring tailored prenatal and postpartum care.

Investigators review medical, surgical, and radiologic methods to manage abnormal uterine bleeding caused by fibroids, highlighting the need for personalized treatment strategies to improve quality of life.

Loneliness, amplified by the pandemic and digital dependence, poses serious health risks, affecting patient outcomes and clinician well-being.

A phase 3 trial found simple hysterectomy is noninferior to radical hysterectomy in preventing pelvic recurrence within 3 years while reducing urologic complications in low-risk, early-stage cervical cancer patients.

In our latest roundtable series, we cover different therapies around COVID-19 treatment and prevention.

A comprehensive analysis shows the benefits of thromboprophylaxis often outweigh the bleeding risks during gynecologic cancer procedures, though patient-specific risk factors are crucial for decision-making.

Discover how fezolinetant offers a safe, effective, and targeted solution for hot flashes, revolutionizing menopause care for women who can’t or won’t use hormones.

In a recent study, patients of all age categories were less likely to conceive if they had low antimüllerian hormone levels, highlighting its potential in reproductive counseling.

A recent review established guidelines for prenatal diagnosis and care of vasa previa, outlining its definition, screening and diagnosis, management, and timing of delivery in asymptomatic patients.

In a recent study, an inverse relationship was discovered between anti-Müllerian hormone levels and early menopause, highlighting the need to develop interventions for fertility preservation based on genetics.

Data released by the Centers for Disease Control and Prevention has indicated reduced abortion rates across multiple subgroups in the United States.

Jason Bell, MD, discusses the impact of living in contraceptive deserts on college-aged women, highlighting the importance of education, access, and support for reproductive health.

The panelist discusses how asymptomatic sexually transmitted infections (STIs) can silently impact overall health, emphasizing the importance of comprehensive screening and education, particularly for less known STIs like trichomoniasis and Mycoplasma genitalium, while exploring how newer testing methods like nucleic acid amplification testing (NAAT) can address challenges in traditional screening access and improve patient care.

In a recent study, endometriosis-associated pain was reduced among patients taking elagolix, with bone mineral density mitigated using add-back therapy.

In a recent study, the prevalence of gynecological cancer trials was reduced in states with high economic vulnerability and minoritized populations.

In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.

Panelists discuss strategies for simplifying complex information for primary care physicians (PCPs), provide tips on how PCPs can effectively communicate evidence-based treatment options to patients, and outline actionable points and key takeaways to enhance patient care in managing menopause symptoms.

Panelists discuss alternative therapies for women who are not candidates for or choose not to use hormonal therapy, review nonhormonal treatment options recommended by the North American Menopause Society, and explore the growing importance of Level I evidence and consensus opinions in creating a more holistic view of available therapies, both hormonal and nonhormonal.

Panelists discuss key considerations for women taking hormonal therapy, emphasizing the importance of individualized treatment plans and shared decision-making to evaluate the risk-benefit profile of therapy.

Panelists discuss clinical trial data suggesting a small but higher incidence of endometrial hyperplasia or malignancy with fezolinetant, while no cases of endometrial hyperplasia or malignancy were observed with elinzanetant in a long-term safety study.

Panelists discuss why elinzanetant is likely to be associated with a lower risk of liver injury due to its distinct molecular structure compared to fezolinetant, and compare the adverse event profiles of the 2 drugs, highlighting that elinzanetant is more commonly associated with headache and fatigue while fezolinetant is linked to abdominal pain, diarrhea, insomnia, and back pain.

Panelists discuss why a warning about serious liver injury was added to the prescribing information for fezolinetant following a postmarketing case of drug-induced liver injury, and review updated guidelines for baseline liver testing, recommended monitoring, symptoms indicating the need to discontinue the medication, and key points for addressing patient concerns about liver health.